Sparian Biosciences Inc.

New York, NY Doing business as Palion Therapeutics

UEI
E6GKXJ7MWV68
CAGE
8EU60
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
245 W 99th St 8b 615, New York, NY 10025, USA
Founded
2017
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Clinical development of SBS-147: first-in-class oral arylepoxamide agonist for pain UG3DA064392 National Institute on Drug Abuse (NIH) $9,360,586
Development of SBS-226, a MOR agonist / DOR antagonist, for OUD UG3DA059278 National Institute on Drug Abuse (NIH) $19,841,335
Development of sigma receptor/DAT dual-targeting compounds to treat stimulant use disorder UG3DA058553 National Institute on Drug Abuse (NIH) $23,597,485
Development of CP-analogs as novel treatments for opioid use disorder. R44DA053846 National Institute on Drug Abuse (NIH) $955,406
Arylepoxamides: a new class of potent, safer analgesics - the expansion of opioid prescribing in recent years to better… UH3DA048379 National Institute on Drug Abuse (NIH) $32,053,834

Similar vendors

Vendor Location Primary NAICS
Epivario Inc. UEI M6ZTFQ3K1WT3 Philadelphia, PA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Jillion Therapeutics Inc. UEI KNVYBLASYW88 NY 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Addinex Technologies, Inc. UEI YMXEEZMA3KT5 New York, NY —
Makscientific LLC UEI J2NHTDAJGK24 Burlington, MA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Artiam Bio Inc. UEI FKJAXBQEDUJ8 Cary, NC 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Sparian Biosciences Inc., doing business as Palion Therapeutics, is a for-profit corporate entity registered in the System for Award Management (SAM) and located in New York City. The company focuses on developing novel pharmaceutical compounds targeting critical medical challenges, particularly in the realm of pain management and substance use disorders. Registered since September 2019, Palion Therapeutics specializes in researching and developing innovative therapeutic compounds that aim to provide alternative treatments to traditional opioid-based medications.

Through federal grant awards from the National Institute on Drug Abuse (NIDA), Sparian Biosciences has been pursuing multiple research and development projects targeting significant public health issues. The company has received substantial cooperative agreement grants to develop compounds like SBS-147 (a non-opioid pain treatment), SBS-226 (a potential treatment for opioid use disorder), and SBS-518 (a potential treatment for stimulant use disorder). These grants, ranging from approximately $3.1 million to $11.8 million, support preclinical and early clinical development stages, including Phase 1 safety studies and proof-of-concept trials. The research focuses on creating novel pharmaceutical interventions that could potentially mitigate the opioid epidemic by developing alternative pain management and addiction treatment solutions. Additionally, the company has engaged in sub-grant work with research institutions like Sloan-Kettering Institute for Cancer Research, demonstrating a collaborative approach to advancing pharmaceutical research in critical medical domains.

Quick answers

Is Sparian Biosciences Inc. registered in SAM.gov?

Yes. Sparian Biosciences Inc.'s SAM.gov registration is active through December 16, 2026.

What is Sparian Biosciences Inc.'s CAGE code?

Sparian Biosciences Inc.'s CAGE code is 8EU60, and its Unique Entity ID (UEI) is E6GKXJ7MWV68.

What is Sparian Biosciences Inc.'s most recent federal award?

Sparian Biosciences Inc.'s most recent federal grant award is Clinical development of SBS-147: first-in-class oral arylepoxamide agonist for pain (UG3DA064392), from National Institute on Drug Abuse (NIH), on July 1, 2025.

On GovTribe

See Sparian Biosciences Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe